News
Pluvicto is a radioligand therapeutic agent containing the active moiety, lutetium-177, which binds to PSMA, a transmembrane protein that is expressed in prostate cancer.
Drugs in the Pipeline
Following a planned interim analysis, the decision to halt the trial was made after a review of data by an independent Data Monitoring Committee.
News
The perioperative period is receiving increased attention as a platform to inhibit cancer progression, according to investigators.
News
Investigators found that men receiving androgen deprivation therapy for prostate cancer had a 1% rate of major adverse cardiovascular events.
ESMO 2021, News
Enzalutamide plus androgen deprivation therapy improved overall survival by 34%.
News
In a randomized controlled study, adding metformin to androgen deprivation therapy for low-tumor-volume metastatic hormone-sensitive prostate cancer significantly delayed development of castration-resistant disease.
News
Androgen deprivation therapy added to radiation therapy (RT) for unfavorable-risk prostate cancer is not associated with an increased risk for cardiovascular mortality compared with RT alone, even among patients with preexisting cardiovascular disease, a study found.
News
The approval was based on data from a phase 3 study that evaluated the efficacy and safety of Camcevi in 137 adults with advanced prostate cancer.
News
The approval was based on data from the phase 2/3 OSPREY and phase 3 CONDOR trials that evaluated the diagnostic performance and safety of Pylarify injection.
News
Men who take 5-alpha-reductase inhibitors while on active surveillance for prostate cancer are less likely to experience cancer progression, according to a new study
